Kaleido Biosciences is a biotechnology company making discoveries in genetic and metabolic diversity of the human microbiome into treatment and therapies for a wide range of diseases that is headquartered in Bedford, Massachusetts and was founded in 2015 by Geoffrey von Maltzahn and Noubar Afeyan.
On September 17, 2017 Kaleido Biosciences completed a venture capital round that brought thier total amount of funding to date to $65 million. The round was led by Flagship Pioneering (lead investor and a number of institutional and individual investors which included Mike Bonney. At the time of announcing their venture funding the company also announced that Mike Bonney will be joining the Kaleido management team and board of directors.
On June 25, 2018 Kaleido Biosciences announced completing their oversubscribed series C funding round with $101 million in funding from Abu Dhabi Investment Authority (ADIA), Fidelity Management and Research Company, Invus, and Rock Springs Capital, Flagship Pioneering, and several undisclosed investors. The company plans on using their series C funding to accelerate the development of its product pipeline by conducting multiple clinical trials in several therapeutic areas of interest to the company.
Geoffrey von Maltzahn
Chief Innovation Officer